ERBB2 and breast cancer: Phage-vaccine anticancer efficacy correlates with the induction of anti-HER2 antibodies, which are able to interfere with HER2 downstream signaling pathways and to reduce cell viability in vitro even in trastuzumab-resistant BC cells.